| pubmed-article:8443817 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0007134 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0034819 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1171362 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0332448 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0334094 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C0870432 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1705417 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:8443817 | lifeskim:mentions | umls-concept:C1555465 | lld:lifeskim |
| pubmed-article:8443817 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8443817 | pubmed:dateCreated | 1993-4-7 | lld:pubmed |
| pubmed-article:8443817 | pubmed:abstractText | The fact that progressing tumors contain a significant infiltrate of T-cells brings into question the competency of the infiltrating T-lymphocytes (T-TIL). We have examined the role of the T-cell receptor/CD3 complex and/or the interleukin 2 receptor (IL2R) in responsiveness of T-cells that infiltrate human renal cell carcinoma. T-TIL display a poor proliferative response to interleukin 2 (IL2) alone, IL2 in combination with antibody to CD3, or mitogen stimulation. The proliferative unresponsiveness was not related to low expression of CD3 or IL2R beta as the percentage of T-cells expressing CD3 and IL2R beta were comparable in both T-TIL and peripheral blood T-cells obtained from the same patient. In contrast to the lack of proliferative activity, stimulation of T-TIL or peripheral blood lymphocytes with phytohemagglutinin or anti-CD3 resulted in comparable levels of both IL2 and gamma-interferon mRNA and protein expression. While levels of IL2R alpha were low in unstimulated T-TIL and peripheral blood lymphocytes, anti-CD3 antibody or IL2 were capable of inducing surface expression of this protein in both cell populations. IL2R alpha mRNA levels were comparable in T-cells from the tumor and peripheral blood although in some experiments both the percentage of IL2R alpha-positive cells and the density of surface expression per cell were reduced in T-TIL. This reduced IL2R alpha expression on T-TIL was not responsible for the proliferative unresponsiveness since T-TIL that expressed both IL2R alpha and/or IL2R beta still failed to respond to high doses of IL2. Thus T-TIL display a selective loss of response to at least two well defined extracellular stimuli. While T-TIL exhibit a poor proliferative response regardless of the form of stimulation these cells remain sensitive to both anti-CD3 and IL2 in terms of IL2 and gamma-interferon or IL2R alpha expression, respectively. The fact that proliferative unresponsiveness exists even though T-TIL can produce IL2 and express IL2R alpha/beta suggests that T-TIL have a selective loss of a common intracellular signaling pathway which is requisite to proliferation but not other aspects of response to antigenic stimulation. | lld:pubmed |
| pubmed-article:8443817 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8443817 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8443817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8443817 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8443817 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8443817 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:KudohSS | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:AlexanderJ... | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:KleinEE | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:BukowskiR MRM | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:HamiltonT ATA | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:TubbsR RRR | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:SicaDD | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:EdingerM GMG | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:TuasonLL | lld:pubmed |
| pubmed-article:8443817 | pubmed:author | pubmed-author:MelsopK AKA | lld:pubmed |
| pubmed-article:8443817 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8443817 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8443817 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:8443817 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8443817 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8443817 | pubmed:pagination | 1380-7 | lld:pubmed |
| pubmed-article:8443817 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:meshHeading | pubmed-meshheading:8443817-... | lld:pubmed |
| pubmed-article:8443817 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8443817 | pubmed:articleTitle | T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. | lld:pubmed |
| pubmed-article:8443817 | pubmed:affiliation | Department of Urology, Cleveland Clinic Foundation, Ohio 44195. | lld:pubmed |
| pubmed-article:8443817 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8443817 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8443817 | lld:pubmed |
